Thursday, 23 Jan 2020

You are here

Bone Marrow Edema Found in SI Joint of Athletes

New research shows that young elite athletes will not commonly manifest bone marrow edema in the SI joint following activity.

A study in Arthritis & Rheumatology  assessed for MRI findings commonly seen in patients with axial spondyloarthropathy (axial Spa). (Citation source: https://buff.ly/2DrlCgB)

Danish researchers studied 20 recreational runners and 22 professional ice hockey players to determine the frequency of bone marrow edema in the sacroiliac joint. The runners received MRI scans of their sacroiliac joints before and 24 hours after a 6.2-km competitive run, and the hockey players received scans at the end of their competitive season.

The proportion fulfilling the ASAS definition concordantly by ≥2/3 readers were 30-35%/41%, respectively. The posterior lower ilium was the single most affected SI joint, followed by the anterior upper sacrum. Erosions were absent and may be the key for discriminating disease from normal variations.

Active athletes may meet ASAS definition in 30%-41% for bone marrow edema. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.